Reagila 3 mg hard capsules

2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia

A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia